New hope for tough lung cancers: ivonescimab combo enters phase 3 trial

NCT ID NCT06928389

Recruiting now Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether adding the experimental drug ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. The study includes 536 adults whose cancer worsened after prior immunotherapy. Participants are randomly assigned to receive either ivonescimab or a placebo, both combined with docetaxel. The main goal is to see if the combination improves overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ivonescimab and docetaxel
What this could lead to: If it works, this could offer a new treatment option for people with advanced lung cancer whose disease has worsened after standard immunotherapy.
What could go wrong: This is still an experimental combination; it may not improve survival or could cause more side effects than the current standard. Results are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.